# A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

> **NCT05630287** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]-Selpercatinib
- **DRUG:** Selpercatinib
- **DRUG:** [14C]-Selpercatinib

## Key facts

- **NCT ID:** NCT05630287
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-09-24
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630287, "A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05630287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*